Biomarkers of Injectable Extended Release Naltrexone Treatment

University of Pennsylvania32 enrolled

Overview

This study evaluates the biological markers of treatment of opioid dependent individuals with an extended release formulation of the opioid antagonist naltrexone. The biological measures include functional MRI, blood levels of naltrexone and its metabolites, urine toxicology and behavioral tests probing various aspects of personality, memory, reward processing and attention.

This study is using blood oxygenation level dependent (BOLD) functional magnetic resonance imaging (fMRI) to examine the brain predictors of adherence and outcomes of opioid antagonist therapy. Opioid-dependent intravenous heroin users are offered up to 3 monthly injections of the extended-release naltrexone (XRNTX) contingent upon successful outpatient non-opioid detoxification, with an additional 4 weeks of follow up. Brain responses to heroin-related pictures are recorded using fMRI prior to the 1st XRNTX injection and approximately 2 weeks thereafter the 1st XRNTX injection. Primary clinical variables include the number of injections (maximum of 3) accepted by participants, change in self-reported craving for opioids after exposure to drug-related visual cues during the brain fMRI sessions, urine levels of ten commonly abused substances and self-report of cigarette use.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Heroin Dependence Opioid Dependence

Interventions

NaltrexoneDRUG

Up to three monthly injections of 380 mg of naltrexone suspended in dissolvable polymer microspheres and administered intramuscularly

Eligibility

Sex: ALLMin age: 18 YearsMax age: 55 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. DSM-IV-TR diagnosis of opioid dependence, active opioid use, confirmed by urine toxicology screen and self-reported monthly intravenous heroin use for more than 2 weeks in the past 3 months 2. urine toxicology screen negative for opioids after detoxification 3. good physical health as indicated by history and physical examination, screening blood work-up and urinalysis. Exclusion Criteria: 1. chronic medical illnesses; 2. current use of medications potentially confounding brain activity, such as anti-dopaminergic agents, anti-depressants and beta-blockers; 3. current DSM-IV-TR Axis I psychiatric disorders other than opioid and nicotine dependence; 4. life time history of concurrent IV cocaine and heroin (speedball) administration; 5. pregnancy or breastfeeding; 6. history of clinically significant head trauma; 7. contraindications for naltrexone treatment including medical conditions requiring opioid analgesics, e.g. chronic pain or planned surgery, obesity, elevated liver enzymes (\> 3 times upper limit of normal), failure to complete opioid detoxification 8. contraindications for MRI, i.e. indwelling magnetically active foreign bodies and phobia to enclosed spaces

Locations (1)

Center for the Studies of Addiction

Philadelphia, Pennsylvania, United States

Outcomes

Primary Outcomes

Brain response to heroin-related visual cues

Brain, behavioral and motivational (e.g. craving) response to audiovisual drug-related and control stimuli (images, smells and sounds) and to standard tasks of decision making, self-appraisal, response inhibition, social interaction and reward processing.

Time frame: 1 hour

Secondary Outcomes

Cigarettes smoked per day

behavioral

Time frame: 6 months

Urine toxicology

Urine toxicology for methamphetamine, amphetamines, cannabis, cocaine, oxycodone, buprenophine, methadone, opioids, benzodiazepines and barbiturates.

Time frame: 6 months

Injections

Number of injections (maximum of 3) accepted by participants

Time frame: 3 months

Motivational response to opioid-related visual cues measured by self-reported craving for opioids

Change in self-reported craving for opioids after exposure to opioid-related visual cues during functional MRI sessions

Time frame: 2 hours

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.